Regenerative Therapies for Lumbar Degenerative Disc Disease

SCIENTIFIC STUDY REVIEW

Featured Article: Regenerative therapies for lumbar degenerative disc diseases: a literature review

Original article: https://doi.org/10.3389/fbioe.2024.1417600

Direct Answer and Clinical Takeaway

• Regenerative approaches such as mesenchymal stromal cells, platelet-rich plasma, growth factors, and biomaterials may improve pain or function in some patients with lumbar degenerative disc disease.
• Evidence that these treatments can regenerate disc tissue remains limited, and improvements in pain or function do not necessarily show that the disc itself has healed.
• These treatments remain investigational and require larger controlled trials with standardized products, imaging outcomes, and safety monitoring over time.

Lumbar degenerative disc disease develops when the discs between the bones of the lower spine lose water and other important components, causing them to break down and function less effectively. These changes may contribute to back pain, disc herniation, instability, and nerve compression, although imaging findings do not always explain a person’s symptoms.

Medication, physical therapy, behavioral care, injections, discectomy, fusion, and artificial-disc replacement can reduce symptoms or stabilize the spine. They do not reliably rebuild a damaged disc or restore its original properties.

A 2024 review by Sono and colleagues examined cell therapies, biomaterials, growth factors, platelet-rich plasma, anti-inflammatory biologics, and combination approaches intended to repair or replace damaged disc tissue. The review found promising early signals, but it did not establish that any regenerative treatment can consistently reverse disc degeneration in routine clinical care.

Purpose and Methodology

The authors summarized laboratory, animal, and human research on regenerative approaches for lumbar disc degeneration. They reviewed disease biology, experimental cells and materials, clinical outcomes, and barriers to clinical use.

This was a narrative literature review, not a systematic review, meta-analysis, or new clinical trial. The authors did not describe a formal search strategy, risk-of-bias assessment, or pooled analysis. The paper is therefore useful for understanding the field, but it cannot determine which treatment works best or calculate a reliable overall treatment effect.

How Lumbar Discs Degenerate

A healthy intervertebral disc has a water-rich center called the nucleus pulposus, a strong outer ring called the annulus fibrosus, and cartilage endplates above and below. Proteoglycans in the center hold water and resist compression, while organized collagen fibers in the outer ring provide tensile strength.

With age or injury, the disc may lose water and proteoglycans, become less cellular, and develop disorganized collagen and annular tears. Disc height can fall, loads can shift, and nerves and blood vessels may grow into normally sparse areas, contributing to pain and mechanical failure.

These structural changes can reinforce one another. Reduced hydration limits the nucleus pulposus’s ability to absorb pressure, while annular fissures and loss of disc height change how forces move through the spinal segment. Bulging, herniation, instability, and nerve compression may follow as the disc becomes less able to distribute normal loads.

Degenerated discs also show an inflammatory environment that may include interleukin-1 beta, interleukin-6, and tumor necrosis factor alpha. Inflammation can increase tissue breakdown and make it more difficult for native or injected cells to survive and function. A regenerative therapy must therefore address both the disc’s biological environment and its mechanical demands.

Cell-Based Regenerative Approaches

Mesenchymal stromal cells have received the most clinical attention. Sources included bone marrow, adipose tissue, peripheral blood, and umbilical cord tissue. These cells are of interest because of their proliferation, chondrogenic differentiation potential, immune-modulating effects, and availability from both autologous and allogeneic sources.

Proposed benefits include direct contribution to extracellular matrix production and indirect effects through paracrine signaling. MSCs may release factors that encourage native cells to adopt a more reparative pattern, limit harmful immune-cell activity, or attract other cells involved in tissue repair.

Environmental stressors inside a degenerated disc may interfere with MSC proliferation, differentiation, and survival. Low nutrient availability, inflammation, altered mechanics, and poor cell retention may prevent an injected product from behaving as it did in laboratory culture.

The review also covered nucleus pulposus cells, disc-derived cells, and chondrocytes, which may suit cartilage-like tissue but present access, expansion, and cell-identity problems. Bone marrow concentrate and stromal vascular fraction contain mixed cells and signals, making their dose, composition, mechanism, and quality difficult to standardize. Induced pluripotent stem cell approaches remain preclinical.

Biomaterials and Other Regenerative Strategies

Injectable hydrogels and other nucleus-replacement materials aim to restore disc height, pressure, or stability. Synthetic products must match disc mechanics and avoid migration, swelling, stiffness, wear, or debris. Biological scaffolds must also support cell survival, integration, and new tissue.

Complete disc replacements combine nucleus-like and annulus-like components, but tissue integration and durability under repeated spinal loading remain major challenges.

Growth factors may stimulate cells and matrix production, while platelet-rich plasma supplies concentrated platelets and signaling proteins. Two randomized trials reported improvements in pain, disability, or walking measures after intradiscal platelet-rich plasma, but formulations, comparators, and delivery methods differed.

Other approaches target inflammatory pathways. Combination strategies pair cells with scaffolds or growth factors, but most remain in small-animal research.

What the Clinical Evidence Showed

Clinical studies of bone marrow-, adipose-, peripheral blood-, and umbilical cord-derived products produced mixed results. Evidence ranged from two-patient case series to randomized studies involving more than 100 participants. Products, processing methods, doses, comparators, outcomes, and follow-up periods differed substantially.

Several studies of bone marrow-, adipose-, and umbilical cord-derived MSCs reported improvements in pain or disability. One randomized phase 2 study followed 60 participants treated with allogeneic bone marrow-derived precursor cells for 36 months. A 33-patient umbilical cord MSC case series reported improvements over 24 months. However, many studies lacked large control groups or consistent structural outcomes.

Findings were not uniform. A ten-patient study of peripheral-blood hematopoietic cells reported no pain improvement. In a four-patient bone marrow MSC series, one participant experienced worsening low-back pain.

The review also included a randomized study with 123 treated participants involving viable disc tissue allograft. This product contained allogeneic spine-derived cells within donor disc tissue and was not a conventional culture-expanded MSC therapy. Its reported improvements in pain and disability cannot be attributed specifically to stromal cells or applied directly to other MSC products.

Two randomized trials evaluated intradiscal platelet-rich plasma. One reported improvements in pain and function through one year. The other reported better disability and walking scores at selected time points than corticosteroid injection. These findings support further study but do not demonstrate restoration of disc structure.

Pain and function are important outcomes, but improvement does not prove that a disc regenerated. Symptoms can change without structural repair, and imaging may not match how a patient feels. The review provided no pooled evidence of consistent recovery in disc height, tissue composition, or normal biomechanics.

Safety and Product Quality

The review described stromal-cell safety findings as generally favorable, with serious events reported infrequently. The review’s evidence table nevertheless included an implantation-site infection in one allogeneic bone marrow-derived precursor-cell study and worsening pain in one participant in a small autologous bone marrow MSC series.

For the viable disc tissue allograft study, the table reports two serious adverse events as 2/141. A disc-derived chondrocyte trial reported treatment-emergent adverse events in six of 12 participants. One randomized platelet-rich plasma trial reported a post-injection pain event. The table does not establish that each event was caused by the product.

Most studies were too small to detect uncommon complications or provide certainty about long-term risk. Safety also depends on donor screening, tissue collection, manufacturing, expansion, storage, sterility, dose, product consistency, and injection technique.

Intradiscal needle placement carries risks independent of the injected product. Material-based therapies add concerns such as migration, swelling, mechanical mismatch, wear, tissue reaction, and failure under repeated load. Combination products create additional manufacturing and regulatory complexity.

Key Limitations of the Evidence

The evidence was highly mixed. It combined cells, biomaterials, platelet products, growth factors, drugs, viable donor tissue, and engineered constructs across different disease stages and study designs. Many clinical reports were early-phase trials or small case series with limited controls.

Animal models also have limits. Rodents aid early screening, and larger animals better match human disc size and mechanics, but no model reproduces the slow course of human disc degeneration. An injured animal disc may not predict durable benefit in chronic back pain.

Other barriers include poor cell survival, uncertain retention, uncontrolled differentiation, limited integration, mechanical instability, inconsistent manufacturing, and incomplete long-term safety data. The review did not formally rank evidence quality or test for publication bias.

What the Review Means for Patients

The review supports further research, not a conclusion that regenerative disc therapy is proven. Early studies reported less pain or disability, but they did not show that an injection reliably restores a damaged disc, prevents surgery, or outperforms established care.

Patients considering stem cells, exosomes, platelet-rich plasma, hydrogels, viable disc tissue, or procedures marketed as disc regeneration should ask what the product contains, whether it is part of a registered clinical trial, what evidence supports that exact product and indication, and how adverse events are monitored.

Evaluation should also confirm that the disc is a plausible source of symptoms. Degeneration on imaging alone does not establish that an experimental intradiscal treatment is appropriate.

Clinical Takeaway

Regenerative strategies for lumbar disc degeneration are biologically plausible. Cells may influence inflammation and matrix production, biomaterials may provide mechanical support, and growth factors or platelet products may stimulate repair. Combined approaches may eventually address several parts of the disease process.

The most encouraging human findings involve pain and disability. Evidence of structural regeneration is much less consistent. Symptom improvement does not demonstrate restored disc height, rebuilt extracellular matrix, tissue integration, or normal mechanical function.

The term regenerative therapy also covers products that are not interchangeable. Culture-expanded MSCs, bone marrow concentrate, stromal vascular fraction, viable donor disc tissue, platelet-rich plasma, growth factors, and scaffolds have different compositions, risks, and regulatory considerations.

These approaches remain investigational. Larger controlled trials need standardized products, clear patient selection, appropriate comparison groups, structural and functional outcomes, and long-term safety monitoring before any therapy can be considered an established method for regenerating lumbar discs.

Reference

Sono T, Shima K, Shimizu T, Murata K, Matsuda S, Otsuki B. Regenerative therapies for lumbar degenerative disc diseases: a literature review. Front Bioeng Biotechnol. 2024;12:1417600. doi:10.3389/fbioe.2024.1417600. View Article

Regulatory Disclaimer

Stemedix provides this review for educational and informational purposes only and represents an academic commentary on published literature. The findings do not establish any treatment as safe or effective and should not be interpreted as medical advice. Products and procedures discussed may be investigational and are not FDA approved for lumbar degenerative disc disease unless explicitly stated otherwise. Consult a qualified physician before changing prescribed care.